By Maryam Cockar
Date: Friday 16 Dec 2016
(ShareCast News) - A regulatory body has accused pharmaceutical Actavis UK of breaking competition law by hiking the price of a hormone replacement drug by 12,000% to the NHS.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 0.00 |
| Closing Price Change | $ 0.00 |
| % Change | 0.00 % |
| 52 Week High | $0.00 |
| 52 Week Low | $0.00 |
| Volume | 0 |
| Shares Issued | 328.60m |
| RiskGrade | 36 |
You are here: research